The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 2 study to evaluate efficacy and safety of PRGN-2009, a novel gorilla adenovirus-based immunotherapy, in combination with pembrolizumab versus pembrolizumab monotherapy in patients with recurrent or metastatic cervical cancer.
 
Nicholas Tschernia
No Relationships to Disclose
 
Michael J. Birrer
Consulting or Advisory Role - AstraZeneca; GlaxoSmithKline; Merck
 
John B. Liao
Consulting or Advisory Role - Verismo Therapeutics
Research Funding - Aminex (Inst); AstraZeneca (Inst); Forty Seven (Inst); Harpoon therapeutics (Inst); Instil Bio (Inst); Laekna Therapeutics (Inst); Merck Sharp & Dohme (Inst); Precigen (Inst); Sanofi (Inst); Sumitomo Dainippon Pharma Oncology (Inst)
Travel, Accommodations, Expenses - Janssen (I)
 
Amy Lankford
Employment - Precigen
Stock and Other Ownership Interests - Precigen; Precigen
 
Mary L. Disis
Stock and Other Ownership Interests - Epithany
Research Funding - Aston Sci. (Inst); Bavarian Nordic (Inst); Precigen (Inst); Veana Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - I am an inventor on patents held by the University of Washington
 
James L. Gulley
Research Funding - Astellas Medivation (Inst); Bavarian Nordic (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); ImmunityBio (Inst); Incyte (Inst); Janssen Oncology (Inst); Kite, a Gilead company (Inst); Marengo Therapeutics (Inst); Merck (Inst); NextCure (Inst); PDS Biotechnology (Inst); Pfizer (Inst); Precigen (Inst); Syndax (Inst); Syntrix Biosystems (Inst)
Patents, Royalties, Other Intellectual Property - COMBINATION PDL1 AND TGF-BETA BLOCKADE IN PATIENTS WITH HPV+ MALIGNANCIES Publication number: 20200062849 Abstract: The invention provides a method of inhibiting a malignancy associated with human papilloma virus (HPV) comprising administering to a subje